共查询到20条相似文献,搜索用时 46 毫秒
1.
Cuscó I Barceló MJ Rojas-García R Illa I Gámez J Cervera C Pou A Izquierdo G Baiget M Tizzano EF 《Journal of neurology》2006,253(1):21-25
Spinal muscular
atrophy (SMA) is an autosomal
recessive disorder that affects
motor neurons. It is caused by
mutations in the survival motor
neuron gene 1 (SMN1). The SMN2
gene, which is the highly homologous
SMN1 copy that is present in
all the patients, is unable to prevent
the disease. An SMN2 dosage
method was applied to 45 patients
with the three SMA types (I–III)
and to four pairs of siblings with
chronic SMA (II–III) and different
phenotypes. Our results confirm
that the SMN2 copy number plays a
key role in predicting acute or
chronic SMA. However, siblings
with different SMA phenotypes
show an identical SMN2 copy number
and identical markers, indicating
that the genetic background
around the SMA locus is insufficient
to account for the intrafamilial
variability. In our results, age of
onset appears to be the most important
predictor of disease severity
in affected members of the
same family.Given that SMN2 is
regarded as a target for potential
pharmacological therapies in SMA,
the identification of genetic factors
other than the SMN genes is necessary
to better understand the
pathogenesis of the disease in order
to implement additional therapeutic
approaches. 相似文献
2.
Harada Y Sutomo R Sadewa AH Akutsu T Takeshima Y Wada H Matsuo M Nishio H 《Journal of neurology》2002,249(9):1211-1219
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disorder that is characterized by degeneration
of the anterior horn cells of the spinal cord, which leads to the axial and limb weakness associated with muscle atrophy.
SMA is classified into three groups based on the clinical severity: type I (severe), type II (intermediate) and type III (mild).
All three clinical subtypes of SMA are caused by mutations of the SMN1 gene. More than 95 % of SMA patients show homozygous deletion of SMN1. It is thought that SMN2, which is a highly homologous gene of SMN1, compensates for the SMN1 deletion to some degree. To clarify the relationship between SMN2 and the disease severity of SMA, we performed fluorescence-based quantitative polymerase chain reaction assay of the copy
number of SMN2 in 27 patients (11 type I and 16 type II–III) homozygous for SMN1 deletion. The SMN2 copy number in type II–III patients was 3.1 ± 0.3 (mean ± SD), which is significantly higher than that observed in type I
patients, 2.2 ± 0.6 (P < 0.01). However, three of the 11 type I patients carried 3 SMN2 copies. A type I patient with 3 SMN2 copies was studied further. RT-PCR analysis of the patient showed a trace of full-length SMN2 mRNA species, but a large amount of the truncated SMN2 mRNA species lacking exon 7. In conclusion, SMN2 alleles are not functionally equivalent among SMA patients, although in general the SMN2 copy number is correlated with the severity of SMA. Genetic background influencing splicing mechanisms of the SMN2 gene may be more critical in some SMA patients.
Received: 11 December 2001, Received in revised form: 14 March 2002, Accepted: 19 March 2002 相似文献
3.
4.
Scarciolla O Stuppia L De Angelis MV Murru S Palka C Giuliani R Pace M Di Muzio A Torrente I Morella A Grammatico P Giacanelli M Rosatelli MC Uncini A Dallapiccola B 《Neurogenetics》2006,7(4):269-276
Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95% of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction–restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers. 相似文献
5.
Shan-Fu Ou Che-Sheng Ho Wang-Tso Lee Kuang-Lin Lin Cynthia C. Jones Yuh-Jyh Jong 《Brain & development》2021,43(1):127-134
IntroductionSpinal muscular atrophy (SMA) is caused by a defect in the survival motor neuron 1 (SMN1) gene. The Cooperative Study of the natural history of SMA Type I in Taiwan is a retrospective, longitudinal, observational study that helps in further understanding SMA disease progression in patients who have not received disease-modifying therapeutic interventions.MethodsCase report forms were used to collect demographics; genetic confirmation; SMN2 copy number; treatment patterns; and clinical outcomes including ventilator use, endotracheal tube intubation, tracheostomy, gastrostomy, complications, and survival.ResultsA total of 111 patients with SMA Type I were identified over the study period (1979–2015). Mean (median) age of onset and age at confirmed diagnosis were 1.3 (0.8) and 4.9 (4.4) months, respectively. SMN1 deletion/mutation was documented in 70 patients and SMN2 copy number in 32 (2 copies, n = 20; 3 copies, n = 12). At 240 months, survival probability for patients born during 1995–2015 versus 1979–1994 was significantly longer (p = 0.0057). Patients with 3 SMN2 copies showed substantially longer 240-month survival versus patients with 2 SMN2 copies. Over the 36-year period, mean (median) age at death was 31.9 (8.8) months. As of December 2015, 95 patients had died, 13 were alive, and 3 were lost to follow-up. The use of supportive measures (tracheostomy and gastrostomy) was associated with improved survival.ConclusionsThese data describe the short survival of patients with SMA Type I in Taiwan in the pretreatment era, emphasizing the positive impact of supportive measures on survival. 相似文献
6.
《Neuromuscular disorders : NMD》2018,28(3):208-215
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss or mutations in SMN1. According to age of onset, achieved motor abilities, and life span, SMA patients are classified into type I (never sit), II (never walk unaided) or III (achieve independent walking abilities). SMN2, the highly homologous copy of SMN1, is considered the most important phenotypic modifier of the disease. Determination of SMN2 copy number is essential to establish careful genotype–phenotype correlations, predict disease evolution, and to stratify patients for clinical trials. We have determined SMN2 copy numbers in 625 unrelated Spanish SMA patients with loss or mutation of both copies of SMN1 and a clear assignation of the SMA type by clinical criteria. Furthermore, we compiled data from relevant worldwide reports that link SMN2 copy number with SMA severity published from 1999 to date (2834 patients with different ethnic and geographic backgrounds). Altogether, we have assembled a database with a total of 3459 patients to delineate more universal prognostic rules regarding the influence of SMN2 copy number on SMA phenotype. This issue is crucial in the present scenario of therapeutic advances with the perspective of SMA neonatal screening and early diagnosis to initiate treatments. 相似文献
7.
H. Nishio Yukitoshi Ishikawa Myeong Jin Lee Yasuhiro Takeshima Hiroko Wada Satoshi Takada Hajime Nakamura Masafumi Matsuo Kimiaki Sumino 《Journal of neurology》1999,246(1):48-52
Most spinal muscular atrophy (SMA) patients lack the survival motor neuron gene (SMN). However, the patients retain at least one copy of the
c
BCD541 gene (BCD), which is highly homologous with SMN. Here, we determined the SMN/BCD copy number ratios (the S/B ratios) of 12 parents of Japanese SMA patients with a homozygous SMN deletion, using competitive oligonucleotide priming polymerase chain reaction. We identified an S/B ratio of 2 in 25% of
the parents examined, whereas less than 2% of parents of SMA patients in Western populations have an S/B ratio of 2. The high
incidence of an S/B ratio of 2 in Japanese parents of SMA patients may reflect the characteristic genetic background of SMA
in Japan.
Received: 5 November 1997 ƒReceived in revised form: 29 May 1998 ƒAccepted: 31 May 1998 相似文献
8.
9.
Yogik Onky Silvana Wijaya Mawaddah Ar Rohmah Emma Tabe Eko Niba Naoya Morisada Yoriko Noguchi Yasufumi Hidaka Shiro Ozasa Takeshi Inoue Tomoyuki Shimazu Yuya Takahashi Takenori Tozawa Tomohiro Chiyonobu Takushi Inoue Tomoyoshi Shiroshita Atsushi Yokoyama Kentaro Okamoto Hiroyuki Awano Yasuhiro Takeshima Masakazu Shinohara 《Brain & development》2021,43(7):745-758
BackgroundSpinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by homozygous deletion or intragenic mutation of the SMN1 gene. It is well-known that high copy number of its homologous gene, SMN2, modifies the phenotype of SMN1-deleted patients. However, in the patients with intragenic SMN1 mutation, the relationship between phenotype and SMN2 copy number remains unclear.MethodsWe have analyzed a total of 515 Japanese patients with SMA-like symptoms (delayed developmental milestones, respiratory failures, muscle weakness etc.) from 1996 to 2019. SMN1 and SMN2 copy numbers were determined by quantitative polymerase chain reaction (PCR) method and/or multiplex ligation-dependent probe amplification (MLPA) method. Intragenic SMN1 mutations were identified through DNA and RNA analysis of the fresh blood samples.ResultsA total of 241 patients were diagnosed as having SMA. The majority of SMA patients showed complete loss of SMN1 (n = 228, 95%), but some patients retained SMN1 and carried an intragenic mutation in the retaining SMN1 (n = 13, 5%). Ten different mutations were identified in these 13 patients, consisting of missense, nonsense, frameshift and splicing defect-causing mutations. The ten mutations were c.275G > C (p.Trp92Ser), c.819_820insT (p.Thr274Tyrfs*32), c.830A > G (p.Tyr277Cys), c.5C > T (p.Ala2Val), c.826 T > C (p.Tyr276His), c.79C > T (p.Gln27*), c.188C > A (p.Ser63*), c.422 T > C (p.Leu141Pro), c.835-2A > G (exon 7 skipping) and c.835-3C > A (exon 7 skipping). It should be noted here that some patients with milder phenotype carried only a single SMN2 copy (n = 3), while other patients with severe phenotype carried 3 SMN2 copies (n = 4).ConclusionIntragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers. 相似文献
10.
11.
Gyu-Hwan Park Shingo Kariya Umrao R. Monani 《Current neurology and neuroscience reports》2010,10(2):108-117
Spinal muscular atrophy (SMA) is a common and often fatal neurodegenerative disease that primarily afflicts infants and young
children. SMA is caused by abnormally low levels of the survival motor neuron (SMN) protein resulting from a combination of
recessively inherited mutations in the SMN1 gene and the presence of an almost identical but partially functional copy gene, SMN2. Absence of the uniquely human SMN2 gene in SMA patients has never been reported because the SMN protein is indispensable for cell survival. Modeling SMA in
animals therefore poses a challenge. This review describes the different strategies used to overcome this hurdle and model
SMA in mice. We highlight new and emerging insights regarding SMA gained by studying the mice and illustrate how the animals
serve as important tools to understand and eventually treat the human disease. 相似文献
12.
Watihayati MS Fatemeh H Marini M Atif AB Zahiruddin WM Sasongko TH Tang TH Zabidi-Hussin ZA Nishio H Zilfalil BA 《Brain & development》2009,31(1):42-45
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the SMN1 gene. The SMN2 gene is highly homologous to SMN1 and has been reported to be correlated with severity of the disease. The clinical presentation of SMA varies from severe to mild, with three clinical subtypes (type I, type II, and type III) that are assigned according to age of onset and severity of the disease. Here, we aim to investigate the potential association between the number of copies of SMN2 and the deletion in the NAIP gene with the clinical severity of SMA in patients of Malaysian origin. Forty-two SMA patients (14 of type I, 20 type II, and 8 type III) carrying deletions of the SMN1 gene were enrolled in this study. SMN2 copy number was determined by fluorescence-based quantitative polymerase chain reaction assay. Twenty-nine percent of type I patients carried one copy of SMN2, while the remaining 71% carried two copies. Among the type II and type III SMA patients, 29% of cases carried two copies of the gene, while 71% carried three or four copies of SMN2. Deletion analysis of NAIP showed that 50% of type I SMA patients had a homozygous deletion of exon 5 of this gene and that only 10% of type II SMA cases carried a homozygous deletion, while all type III patients carried intact copies of the NAIP gene. We conclude that there exists a close relationship between SMN2 copy number and SMA disease severity, suggesting that the determination of SMN2 copy number may be a good predictor of SMA disease type. Furthermore, NAIP gene deletion was found to be associated with SMA severity. In conclusion, combining the analysis of deletion of NAIP with the assessment of SMN2 copy number increases the value of this tool in predicting the severity of SMA. 相似文献
13.
14.
《Brain & development》2022,44(7):462-468
BackgroundSpinal muscular atrophy (SMA) is a neuromuscular disease mainly caused by the absence of both copies of the survival motor neuron 1 (SMN1) gene. Multiple regions recommended population-wide SMA screening to quantify the copy number of SMN1. SMN1 diagnostic assays for the simplified procedure, high sensitivity, and throughput continue to be needed.MethodsReal-time PCR with high-resolution melting for the quantifying of the SMN1 gene exon 7 copies and exon 8 copies were established and confirmed by multiplex ligation-dependent probe amplification (MLPA). The diagnosis of 2563 individuals, including SMA patients, suspected cases, and the general population, was tested by real-time PCR. The results were compared with the gold standard test MLPA.ResultsIn this study, the homozygous and heterozygous deletions were detected by real-time PCR with a high-resolution melting method with an incidence of 10.18% and 2.26%, respectively. In addition, the R-value distribution (P > 0.05) among 8 replicates and the coefficient of variation (CV < 0.003) suggested that the real-time PCR screening test had high reproducibility. High concordance was obtained between real-time PCR with high-resolution melting and MLPA.ConclusionsThe real-time PCR based on high-resolution melting provides a sensitive and high-throughput approach to large-scale SMA carrier screening with low cost and labor. 相似文献
15.
Tomoto Yamamoto Hideyuki Sato Poh San Lai Dian Kesumapramudya Nurputra Nur Imma Fatimah Harahap Satoru Morikawa Noriyuki Nishimura Takashi Kurashige Tomohiko Ohshita Hideki Nakajima Hiroyuki Yamada Yoshinobu Nishida Soichiro Toda Jun-ichi Takanashi Atsuko Takeuchi Yumi Tohyama Yuji Kubo Kayoko Saito Yasuhiro Takeshima Masafumi Matsuo Hisahide Nishio 《Brain & development》2014
Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by deletion or intragenic mutation of SMN1. SMA is classified into several subtypes based on clinical severity. It has been reported that the copy number of SMN2, a highly homologous gene to SMN1, is associated with clinical severity among SMA patients with homozygous deletion of SMN1. The purpose of this study was to clarify the genotype-phenotype relationship among the patients without homozygous deletion of SMN1. Methods: We performed molecular genetic analyses of SMN1 and SMN2 in 112 Japanese patients diagnosed as having SMA based on the clinical findings. For the patients retaining SMN1, the PCR or RT-PCR products of SMN1 were sequenced to identify the mutation. Results: Out of the 112 patients, 106 patients were homozygous for deletion of SMN1, and six patients were compound heterozygous for deletion of one SMN1 allele and intragenic mutation in the retained SMN1 allele. Four intragenic mutations were identified in the six patients: p.Ala2Val, p.Trp92Ser, p.Thr274TyrfsX32 and p.Tyr277Cys. To the best of our knowledge, all mutations except p.Trp92Ser were novel mutations which had never been previously reported. According to our observation, clinical severity of the six patients was determined by the type and location of the mutation rather than SMN2 copy number. Conclusion: SMN2 copy number is not always associated with clinical severity of SMA patients, especially SMA patients retaining one SMN1 allele. 相似文献
16.
Spinal muscular atrophy (SMA) is a common autosomal recessive disorder, caused by homozygous deletion of the survival motor neuron gene 1 (SMN1). SMN2, a gene highly homologous to SMN1, is considered to influence the severity of SMA. Patients with SMA have been classified into three types on the basis of age at onset and clinical severity. In the present study, we performed a quantitative analysis of SMN2 in 22 patients of SMA to further clarify the correlation between clinical severity and SMN2 gene dosage. We determined the SMN2 gene copy number based on real-time PCR. In 3 Type I patients with only one SMN2 copy, the clinical phenotype was the severest. The remaining 14 Type I patients had two or three copies of the SMN2 gene, and showed a variable clinical severity. A patient with 3 copies required artificial ventilation at 2 months old. Five Type II and Type III patients had at least 4 copies of the SMN2 gene. Although the SMN2 gene dosage correlates the clinical severity, the mechanism by which SMN2 shows compensation in some Type I patients remains to be determined. 相似文献
17.
Emma Tabe Eko Niba Hisahide Nishio Yogik Onky Silvana Wijaya Poh San Lai Takenori Tozawa Tomohiro Chiyonobu Misaki Yamadera Kentaro Okamoto Hiroyuki Awano Yasuhiro Takeshima Toshio Saito Masakazu Shinohara 《Brain & development》2021,43(2):294-302
BackgroundSpinal muscular atrophy (SMA) is a neuromuscular disease caused by homozygous deletion of SMN1 exons 7 and 8. However, exon 8 is retained in some cases, where SMN2 exon 7 recombines with SMN1 exon 8, forming a hybrid SMN gene. It remains unknown how the hybrid SMN gene contribute to the SMA phenotype.MethodWe analyzed 515 patients with clinical suspicion for SMA. SMN1 exons 7 and 8 deletion was detected by PCR followed by enzyme digestion. Hybrid SMN genes were further analyzed by nucleotide sequencing. SMN2 copy number was determined by real-time PCR.ResultsSMN1 exon 7 was deleted in 228 out of 515 patients, and SMN1 exon 8 was also deleted in 204 out of the 228 patients. The remaining 24 patients were judged to carry a hybrid SMN gene. In the patients with SMN1 exon 7 deletion, the frequency of the severe phenotype was significantly lower in the patients with hybrid SMN gene than in the patients without hybrid SMN gene. However, as for the distribution of SMN2 exon 7 copy number among the clinical phenotypes, there was no significant difference between both groups of SMA patients with or without hybrid SMN gene.ConclusionHybrid SMN genes are not rare in Japanese SMA patients, and it appears to be associated with a less severe phenotype. The phenotype of patients with hybrid SMN gene was determined by the copy number of SMN2 exon 7, as similarly for the patients without hybrid SMN gene. 相似文献
18.
Bakri Elsheikh MBBS MRCP Thomas Prior PhD Xiaoli Zhang PhD Robert Miller MD Stephen J. Kolb MD PhD Dan Moore PhD Walter Bradley DM FRCP Richard Barohn MD Wilson Bryan MD Deborah Gelinas MD Susan Iannaccone MD Robert Leshner MD Jerry R. Mendell MD Michelle Mendoza PT Barry Russman MD Stephen Smith MD Wendy King PT John T. Kissel MD 《Muscle & nerve》2009,40(4):652-656
To evaluate the effect of SMN2 copy number on disease severity in spinal muscular atrophy (SMA), we stratified 45 adult SMA patients based on SMN2 copy number (3 vs. 4 copies). Patients with 3 copies had an earlier age of onset and lower spinal muscular atrophy functional rating scale (SMAFRS) scores and were more likely to be non‐ambulatory. There was, however, no difference between the groups in quantitative muscle strength or pulmonary function testing. Functional scale may be a more discriminating outcome measure for SMA clinical trials. Muscle Nerve, 2009 相似文献
19.
A novel mutation at the N-terminal of SMN Tudor domain inhibits its interaction with target proteins
Kotani T Sutomo R Sasongko TH Sadewa AH Gunadi Minato T Fujii E Endo S Lee MJ Ayaki H Harada Y Matsuo M Nishio H 《Journal of neurology》2007,254(5):624-630
Abstract
Although most patients with spinal muscular atrophy (SMA) are homozygous for deletion of the SMN1 gene, some patients bear one SMN1 copy with a subtle mutation. Detection of such an intragenic mutation may be helpful not only in confirming diagnosis but
also in elucidating functional domains of the SMN protein. In this study, we identified a novel mutation in SMN1 of two Japanese patients with type I SMA. DHPLC and sequencing analysis revealed that they harbored a point mutation in SMN1 exon 3, 275G > C, leading to tryptophan-to-serine substitution at amino acid 92 (W92S) at the Nterminal of SMN Tudor domain.
In-vitro protein binding assays showed that the mutation severely reduced interaction of the domain with SmB protein and fibrillarin,
suggesting that it impairs the critical function of SMN. In conclusion, we reported here that a novel mutation, W92S, in the
Tudor domain affects the interaction of SMN with the target proteins. 相似文献
20.
《Neuromuscular disorders : NMD》2010,20(11):744-752
In Spinal Muscular Atrophy (SMA), the SMN1 gene is deleted or inactivated. Because of a splicing problem, the second copy gene, SMN2, generates insufficient amounts of functional SMN protein, leading to the death of spinal cord motoneurons. For a “severe” mouse SMA model (Smn −/−, hSMN2 +/+; with affected pups dying at 5–7 days), which most closely mimicks the genetic set-up in human SMA patients, we characterise SMA-related ultrastructural changes in neuromuscular junctions (NMJs) of two striated muscles with discrete functions. In the diaphragm, but not the soleus muscle of 4-days old SMA mice, mitochondria on both sides of the NMJs degenerate, and perisynaptic Schwann cells as well as endoneurial fibroblasts show striking changes in morphology. Importantly, NMJs of SMA mice in which a modified U7 snRNA corrects SMN2 splicing and delays or prevents SMA symptoms are normal. This ultrastructural study reveals novel features of NMJ alterations – in particular the involvement of perisynaptic Schwann cells – that may be relevant for human SMA pathogenesis. 相似文献